RISK-STRATIFIED SCREENING FOR UROGENITAL MALIGNANCIES: CURRENT EVIDENCE AND FUTURE PERSPECTIVES
Keywords:
Urogenital malignancies; Risk-stratified screening; Early detection; Biomarkers; Artificial intelligence; Precision medicine.Abstract
Urogenital malignancies, including prostate, bladder, kidney, and testicular cancers, are major contributors to global cancer morbidity and mortality. Early detection improves treatment outcomes; however, universal screening has limitations such as over diagnosis, false-positive results, and unnecessary interventions. Risk-stratified screening has emerged as a personalized approach that identifies individuals most likely to benefit from screening based on factors such as age, family history, genetic predisposition, lifestyle, and environmental exposures. Recent advances in multiparametric magnetic resonance imaging (mpMRI), molecular biomarkers, liquid biopsy, and artificial intelligence (AI) have further improved the accuracy of early cancer detection. This review summarizes current evidence on risk-based screening strategies for major urogenital malignancies, highlights emerging diagnostic technologies, discusses current challenges, and explores future directions toward precision oncology. Personalized screening has the potential to improve early diagnosis, reduce unnecessary procedures, and optimize healthcare resources while improving patient outcomes.
References
1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263.
2.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2025. CA Cancer J Clin. 2025;75(1):17–48.
3.US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901–1913.
4.Mottet N, Cornford P, van den Bergh RCN, et al. EAU Guidelines on Prostate Cancer. European Association of Urology; 2025.
5.Pashayan N, Pharoah PDP. The challenge of risk-stratified screening in precision medicine. Nat Rev Clin Oncol. 2020;17(1):41–52.
6.Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multiparametric MRI and targeted biopsy in prostate cancer (PROMIS). Lancet. 2017;389:815–822.
7.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2025.
8.Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the ERSPC trial. N Engl J Med. 2012;366:981–990.
9.Drost FJH, Osses DF, Nieboer D, et al. Prostate MRI with or without MRI-targeted biopsy in prostate cancer diagnosis: systematic review and meta-analysis. Eur Urol. 2020;77(1):78–94.
10.Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update. Eur Urol. 2018;74(6):784–795.
11.Ljungberg B, Albiges L, Abu-Ghanem Y, et al. EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2025.
12.Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic prostate cancer outcomes. Eur Urol. 2015;68(2):186–193.
13.Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2024.
14.Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of biomarkers for prostate cancer detection and risk stratification. Eur Urol. 2021;79(4):493–505.
15.Penzkofer T, Kuhl C, et al. Artificial intelligence and precision imaging in urologic oncology: current applications and future directions. Eur Urol Focus. 2023;9(2):235–244.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal